Fundraising Fox
/Companies
Sign in

Hunterian Medicine

Baltimore, US · Delaware LLC

Find your way into Hunterian Medicine

Sign up to find every way you can get introduced to Hunterian Medicine

  • Your email: who you already know at Hunterian Medicine, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Hunterian Medicine team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Hunterian Medicine develops a CRISPR delivery technology using adeno-associated viruses to enable in vivo gene editing for treating genetic diseases. The company targets rare genetic disorders including cystic fibrosis, muscular dystrophy, and ALS, where existing treatments remain unavailable for the vast majority of cases.

AI & Machine LearningBiotechDeep TechMedical Devices

Founders & leadership

DV
Dr. Vinod Jaskula-RangaFounder, President and CEO

Reported raises · per SEC filings

Form D private placements

$4.6M disclosed across 1 round · 2016

▶$4.6MraisedSep 2024 · 26 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Vinod Jaskula-RangaExecutive Officer, Director
Amount sold
$4.6M
Minimum investment
$50K
First sale
Sep 2016
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

Ascidian TherapeuticsAscidian Therapeutics is a biotechnology company developing RNA-based therapeutics, with a clinical focus that includes ophthalmology and inherited retinal diseases.
Generian PharmaceuticalsGenerian Pharmaceuticals is a preclinical biotechnology company developing orally available small molecule therapeutics for diseases with high unmet need, particularly conditions currently treated by biologics. It targets age-related diseases including metabolic disorders, neurodegeneration, and inflammation.
Lyterian TherapeuticsLyterian Therapeutics develops pharmaceutical treatments by leveraging protein homeostatic mechanisms to target genetically-validated disease drivers. The company focuses on transformative medicines for patients across multiple disease areas.
Viridian TherapeuticsViridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.

Companies working in the same space as Hunterian Medicine.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$350K
National Institutes of Health (NIH)National Institutes of HealthPhase I2022$320K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Hunterian Medicine do?
Hunterian Medicine develops a CRISPR delivery technology using adeno-associated viruses to enable in vivo gene editing for treating genetic diseases. The company targets rare genetic disorders including cystic fibrosis, muscular dystrophy, and ALS, where existing treatments remain unavailable for the vast majority of cases.
Who founded Hunterian Medicine?
Hunterian Medicine was founded by Dr. Vinod Jaskula-Ranga.
How much funding has Hunterian Medicine raised?
Hunterian Medicine has disclosed $4.6M raised across 1 round.
Where is Hunterian Medicine headquartered?
Hunterian Medicine is headquartered in Baltimore, US.